#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Infective uveitis Small cell lung cancer recurrent X-linked lymphoproliferative syndrome Hidradenitis Immunoglobulin G4 related disease Hodgkin's disease Depression Anaplastic large cell lymphoma T- and null-cell types Congenital cystic kidney disease Inborn error of metabolism Toxic epidermal necrolysis Obliterative bronchiolitis Neuroblastoma Hairy cell leukaemia Lymphangioma More trials…

    Learn about Rare Diseases

    Leiomyosarcoma recurrent – Trials in Disease Adrenocortical carcinoma – Treatment Waldenstrom’s macroglobulinaemia recurrent – Life with Disease Leiomyosarcoma recurrent – Diagnostics Alternating hemiplegia of childhood – Treatment Burkitt’s lymphoma – Trials in Disease Mastocytosis – Trials in Disease Short-bowel syndrome – Diagnostics Mantle cell lymphoma – Diagnostics IgA nephropathy – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Rineterkib Other Blood Products Neridronate Sodium Fludarabine Phosphate Ph. Eur. Medroxyprogesterone Acetate Anhydrous Benzoyl Peroxide Radium Ra 223 Dichloride E.coli Polysaccharide Iohexol Asciminib Aminohippuric Acid Omalizumab Sultiame Pevonedistat Pantoprazole Protamine Sulfate Satralizumab Olanzapine MAGNESIUM ACETATE TETRAHYDRATE Adapalene More therapies…

    Learn about Your Condition

    Coeliac disease Tetanus Vascular graft thrombosis Substance use disorder Malignant melanoma stage IV Partial seizures Krabbe's disease Hypertonic bladder Breast cancer in situ Medulloblastoma Hairy cell leukaemia recurrent Neuroblastoma recurrent Alveolar bone defect Takayasu's arteritis Supraventricular tachycardia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Chronic myeloid leukaemia

  • Safety and effectiveness of ponatinib and asciminib in chronic myeloid leukemia patients resistant to these drugs

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Asciminib Hydrochloride
    • Ponatinib
    Spain

  • Asciminib in Pediatric Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Asciminib Hydrochloride
    France Germany Greece Italy The Netherlands Poland +1

  • Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Asciminib Hydrochloride
    • Bosutinib
    • Dasatinib
    Austria Bulgaria Czechia Denmark France Germany +8

  • Study of Olverembatinib and Bosutinib for Patients with Chronic Phase Chronic Myeloid Leukemia

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Chronic myeloid leukaemia
    Investigated Drugs:
    • OLVEREMBATINIB
    • Bosutinib
    Belgium France Germany Italy Poland Spain

  • Study on Apixaban, Rivaroxaban, and Aspirin for Preventing Blood Clots in Patients with JAK2V617F-Positive Myeloproliferative Neoplasms

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Essential thrombocythaemia
    • Myeloproliferative neoplasm
    • Primary myelofibrosis
    Investigated Drugs:
    • Acetylsalicylic Acid
    • Apixaban
    • Rivaroxaban
    France

  • Study of Pioglitazone and Avelumab Combined with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Complete Cytogenetic Response

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Pioglitazone
    • Avelumab
    France
1 2 3 … 5
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!